# Program 12: Developmental Therapeutics

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $40,758

## Abstract

Developmental Therapeutics Program
Project Summary / Abstract
The Developmental Therapeutics (DT) Program comprises a highly collaborative effort across consortium
member institutions. It focuses on the earliest phases of bench-to-bedside preclinical and clinical evaluation of
promising new anti-cancer drugs from the NCI, from DF/HCC research laboratories, and from industry. Among
clinical trials, the Program focuses on disease-agnostic Phase 1 trials, many with expansion cohorts or Phase
2 components that cross cancer types. Strategically, the Program is tightly integrated as a DF/HCC “hub.” On
the one hand, it aligns closely with the Center’s basic science Programs in such areas as signal transduction,
DNA repair, cell cycle regulation, epigenetics, and immuno-oncology. On the other hand, it partners effectively
with DF/HCC’s disease-based Programs: once early evaluation is completed to satisfaction, DT transitions
drugs for later phases of development in disease-specific Programs.
The Program’s 77 members (30 primary and 47 secondary) represent six DF/HCC institutions and 12
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $4.6 million in
direct costs from the NCI and $0.9 million from other sponsors. During the current funding period, primary DT
members published 636 cancer-relevant papers. Of these, 30% were inter-institutional, 9% were intra-
programmatic, and 62% were inter-programmatic collaborations between two or more DF/HCC members. This
scope of inter-Program interactions reflects DT’s role as a genuine “hub” within the Cancer Center, where the
Program also hosts NCI-sponsored U54, UM1, MATCH, and other cooperative agreements for collaborative
early drug development.
Three Specific Aims are planned over the next CCSG funding period: (1) Design and conduct early phase
clinical trials of the most promising new anti-cancer agents and combinations with safety, pharmacokinetic,
pharmacodynamic and preliminary efficacy endpoints, with incorporation of biomarkers for drug response,
resistance and toxicity; (2) Increase participation of minority and underserved populations in early phase
clinical trials; and (3) Provide mentoring and career development support for early career investigators in early
drug development. DF/HCC’s extensive infrastructure for transdisciplinary collaboration, clinical trial review and
conduct, community engagement, biostatistics, education, and training will be instrumental in achieving these
Program goals.

## Key facts

- **NIH application ID:** 10768677
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Geoffrey I. Shapiro
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $40,758
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768677

## Citation

> US National Institutes of Health, RePORTER application 10768677, Program 12: Developmental Therapeutics (5P30CA006516-59). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10768677. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*